Groundbreaking Lung Cancer Trial Uses Innovative Tri-Drug Approach
Oct 30, 2017 08:53AM ● Published by Digital Media Director
Avera will be one of eight sites in the world participating in a groundbreaking new clinical trial for first-line treatment of metastatic non-small cell lung cancer.
The clinical trial is part of the Worldwide Innovative Networking (WIN) Consortium and recently received U.S. Food and Drug Administration (FDA) approval. It is the latest in several planned trials to be offered at Avera, which will improve patient access to cutting edge clinical research in the Sioux Falls region.
“This win for Sioux Falls is two-fold: it’s a good opportunity for patients who have advanced lung cancer but is also a sign of hope for the future. What we learn from these studies can be very important for treatments down the road,” says oncologist Benjamin Solomon, MD, the lead investigator for the study at Avera.
In the Survival Prolongation by Rationale Innovative Genomics (SPRING) trial, patients will be provided a three-drug protocol that incorporates immunotherapy (avelumab) and two other therapies (palbociclib and axitinib). These three targeted drugs used in combination are expected to be highly potent but must be carefully tailored to the patient.
The trial will further results from WIN’s first clinical trial and validate a novel algorithm SIMS (Simplified Interventional Mapping System) developed to match each patient’s tumor biology to a specific drug combination.
SPRING’s investigator-initiated research will be launched in five countries and eight WIN member sites, including two in the US. “Avera must have a high level of expertise to perform these studies,” Solomon said. “This is a testament to the level of ingenuity and knowledge Avera patients have access to. This is not something that can be done everywhere.”
The SPRING trial will start with a Phase I portion to explore the safety of the combination and determine the optimal doses for Phase II that will explore the efficacy of this tri-therapy regimen in first-line treatment of metastatic non-small cell lung cancer. The trial will have strict eligibility criteria and limited enrollment.